Intrarectal administration of 5-aminosalicylic acid (5-ASA) to rabbits and dogs was performed to obtain safety data. Groups of rabbits and dogs received twice daily intrarectal doses of 250, 500 or 1000 mg 5-ASA for 14 consecutive days. Treatment had no adverse effect on the behaviour or performance of the animals and microscopic examination revealed no evidence of systemic or local toxicity.
Azad Khan AK , Piris J , Truelove SC . An experiment to determine the active moiety of sulfasalazine . Lancet1977; 2: 892–895 .
2.
Das KM , Eastwood MA , Mcmanus JPA , Sircus W . The metabolism of salicylazosulfapyridine in ulcerative colitis . Gut1973; 14: 631–641 .
3.
Harris DW , Smoth PR , Swan HJ . Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease . Gut1978; 19: 975-975 .
4.
Gould SR . Prostaglandins, ulcerative colitis and sulfa salazine . Lancet II1975; 2: 988-988 .
5.
Lagumsky M , Karmeli F , Sharon P , Zor U , Cohen F , Rachmilewitz D . Enhanced thromboxane A2 and prostacyclin production in ulcerative colitis and its inhibition by steroids and sulfasalzine . Gastroenterology1981; 81: 444–449 .
6.
Hoult JRS , Moore PK . Effects of sulfasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle . Br J Pharmacol1980; 68: 719–730 .
7.
Goldin E , Achmilewitz D . Prostanoid cytoprotecxtion for maintaining remission in ulcerative colitis <Eth> failure of 151, 15-methylprostaglandin E2 . Dig Dis Sci1983; 28: 807–811 .
8.
Ahnfelt-Ronne I , Haagen Nielsen O . The anti-inflammatory moiety of SAS 5-aminosalicylic acid is a radical scavenger . Agents Actions1987; 21: 192–194 .
9.
Norlander B , Gotthard R , Ström M . Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form . Aliment Pharmacol Ther1989; 3: 333–342 .
10.
Jacobsen BA , Abildgaard K , Rasmussen HH , et al. Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions . Scand J Gastroenterol1991; 26: 374–378 .
11.
Campieri M , Lanfranchi GA , Bazzocchi G , et al. Treatment of ulcerative colitis with high-dose 5-amino salicylic acid enemas . Lancet1981; 2: 270–271 .
12.
Campieri M , Lanfranchi GA , Brignola C , et al. High dose 5-aminosalycilic acid enemas in the treatment of ulcerative colitis . Gastroenterology1984; 5: 164–171 .
13.
Klotz U . Clinical pharmacokinetics of sulfasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid . Clin Pharmacokinet1985; 10: 285–302 .
14.
Rasmussen SN , Bondesen S , Hvidberg EF , et al. 5-Aminosalicylic acid in a slow release preparation: bioavailability, plasma level, and excretion in humans . Gastroenterology1982; 83: 1062–1070 .
15.
Dew MJ , Rider REJ , Evans N , Evans BK , Rhodes J . Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis . Br J Pharmacol1983; 16: 185–187 .
16.
Bilyard KG , Joseph EC , Metcalf R . Mesalazine: an overview of key preclinical studies . Scand J Gastroenterol1990; 25: 52–55 .
